| 產(chǎn)品名稱 |
T529-15D3-18-1A3-1B7 [1B7, CTCC 10752] |
| 商品貨號 |
B161760 |
| Organism |
Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
killing cancer cells. |
| Applications |
The hybrid hybridoma cell lines 1B7 and 1A7 produce bispecific antibodies that recognize both the human Fc gamma receptor III (hFc gamma IIIR) and the multi-drug resistance antigen, P-glycoprotein. The 1B7 and the 1A7 antibodies are capable of binding to both the Fc receptors of cytotoxic cells, and tumor cells exhibiting multi-drug resistance phenotype, wherein the tumor cells over-express P-glycoproteins as compared to normal cells. These bispecific antibodies are useful in killing cancer cells. |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against the human Fc gamma receptor III (hFc gamma IIIR) and the multi-drug resistance antigen, P-glycoprotein |
| Cellular Products |
immunoglobulin; monoclonal antibody; against the human Fc gamma receptor III (hFc gamma IIIR) and the multi-drug resistance antigen, P-glycoprotein |
| Comments |
The hybrid hybridoma cell lines 1B7 (ATCC HB-10500) and 1A7 (ATCC HB-10501) were formed by the fusion of the 15D3 (ATCC HB-11342) and 3G8 hybridoma cell lines. The murine hybridoma 15D3 recognizes the human multi-drug resistance antigen, P-glycoprotein. The murine hybridoma 3G8 recognizes the human Fc gamma receptor III. The hybrid hybridoma cell lines 1B7 and 1A7 produce bispecific antibodies that recognize both the human Fc gamma receptor III (hFc gamma IIIR) and the multi-drug resistance antigen, P-glycoprotein. The 1B7 and the 1A7 antibodies are capable of binding to both the Fc receptors of cytotoxic cells, and tumor cells exhibiting multi-drug resistance phenotype, wherein the tumor cells over-express P-glycoproteins as compared to normal cells. These bispecific antibodies are useful in killing cancer cells. |
| Complete Growth Medium |
Iscove's modified Dulbecco's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate supplemented with 1% OPI (0.15 mg/ml oxaloacetate, 0.05 mg/ml pyruvate, 0.0082 mg/ml bovine insulin), 90%; heat-inactivated fetal bovine serum, 10%
|
| Subculturing |
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml. Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml. |
| Cryopreservation |
culture medium 95%; DMSO, 5% |
| Culture Conditions |
Temperature: 37.0°C |
| Isotype |
IgG1; kappa light chain |
| Name of Depositor |
Chiron Corp. |
| Deposited As |
mouse (B cell); mouse (myeloma) |
| U.S. Patent Number |
|
| References |
Ring D, Shi TX. Monoclonal anti-multiple drug resistance antibody, methods of production and uses thereof. US Patent 6,143,873 dated Nov 7 2000
Ring D, Shi TX. Bispecific antibodies, methods of production and uses thereof. US Patent 5,959,084 dated Sep 28 1999
Ring D, Shi TX. Bispecific antibodies, methods of production and uses thereof. US Patent 6,106,833 dated Aug 22 2000
|
